Piper Sandler raised the firm’s price target on Biogen (BIIB) to $157 from $118 and keeps a Neutral rating on the shares. The firm notes that Biogen shares have certainly participated in the broader rally of the biopharma space in recent months, with the stock up about 35% since the beginning of Q3 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Stoke Therapeutics announce publication of data from BUTTERFLY study
- Stoke Therapeutics, Biogen publish final data from BUTTERFLY study
- Biogen says CHMP adopts positive opinion on high dose regimen of nusinersen
- Biogen, Eisai announce LEQEMBI dosing has been approved in United Kingdom
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls